Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

Purpose National comprehensive cancer network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple-negative breast cancer (TNBC) if the tumor is > 1 cm and consideration of adjuvant chemotherapy for T1b but not T1a disease. These recommendations are based upon sparse dat...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2022-02, Vol.192 (1), p.163-173
Main Authors: Fasano, Genevieve A., Bayard, Solange, Chen, Yalei, Varella, Leticia, Cigler, Tessa, Bensenhaver, Jessica, Simmons, Rache, Swistel, Alexander, Marti, Jennifer, Moore, Anne, Andreopoulou, Eleni, Ng, John, Brandmaier, Andrew, Formenti, Silvia, Ali, Haythem, Davis, Melissa, Newman, Lisa
Format: Article
Language:English
Subjects:
Adjuvant treatment
Analysis
Breast cancer
Breast Neoplasms
Cancer
Cancer research
Chemotherapy
Chemotherapy, Adjuvant
Epidemiology
Female
Humans
Medicine
Medicine & Public Health
Neoplasm Staging
Oncology
Retrospective Studies
Survival
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose National comprehensive cancer network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple-negative breast cancer (TNBC) if the tumor is > 1 cm and consideration of adjuvant chemotherapy for T1b but not T1a disease. These recommendations are based upon sparse data on the role of adjuvant chemotherapy in T1a and T1b node-negative TNBC. Our objective was to clarify the benefits of chemotherapy for patients with T1N0 TNBC, stratified by tumor size. Methods We performed a retrospective analysis of survival outcomes of TNBC patients at two academic institutions in the United States from 1999 to 2018. Primary tumor size, histology, and nodal status were based upon surgical pathology. The Kaplan–Meier plot and 5-year unadjusted survival probability were evaluated. Results Among 282 T1N0 TNBC cases, the status of adjuvant chemotherapy was known for 258. Mean follow-up was 5.3 years. Adjuvant chemotherapy was delivered to 30.5% of T1a, 64.7% T1b, and 83.9% T1c ( p  
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-021-06481-4